Akebia Therapeutics, Inc.
A maker of medicines for people with kidney disease, Akebia developed Vafseo, an oral pill that treats anemia in adults on dialysis, and also sells Auryxia for kidney patients. Founded in 2007 in Cambridge, Massachusetts, the company grew through a merger with Keryx Biopharmaceuticals. Its name comes from the Akebia plant, a fragrant flowering vine nicknamed the "chocolate vine" for its sweet, vanilla-like scent.
Granted 4.51M · Bought 137.1K · Sold 926.4K
Bought 182.6K
Bought 1.60M
Bought 182.6K
Granted 1.21M · Bought 27.0K · Sold 303.3K
Granted 748.9K · Sold 76.3K
Granted 861.8K · Sold 244.5K
Granted 767.0K · Bought 3.5K · Sold 177.1K
Granted 702.2K · Sold 140.4K
Granted 519.3K
Granted 533.8K · Sold 87.3K
Granted 402.9K · Sold 108.1K
Granted 186.2K · Bought 50.0K
Granted 216.8K · Sold 9.8K
Granted 197.4K
Granted 186.2K · Bought 15.0K · Sold 4.6K
Granted 201.2K · Sold 27.3K
Granted 190.0K · Sold 69.8K
Granted 158.8K
Granted 165.2K
Granted 160.7K · Bought 5.8K · Sold 13.7K
Granted 145.1K
Granted 170.5K · Bought 5.0K · Sold 7.0K
Granted 109.4K
Granted 100.5K · Sold 3.5K
Granted 60.0K
Granted 58.6K
Granted 48.6K
Granted 31.1K
Granted 27.4K · Bought 1.3K · Sold 4.6K
Granted 51.5K · Sold 38.0K
Granted 13.7K
Bought 5.0K
Bought 1.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Butler John P.CEO and President, Director · 51 transactions | — | 3.53M | 4.51M | 137.1K | 926.4K |
| Novartis Bioventures Ltd10% owner · 2 transactions | — | 3.41Mas of Mar 2014 | — | 182.6K | — |
| Satter Muneer ADirector · 15 transactions | — | 3.04Mas of Jul 2017 | — | 1.60M | — |
| Novo A/SReporting owner · 2 transactions | — | 1.33Mas of Mar 2014 | — | 182.6K | — |
| Burke Steven KeithSVP, Chief Medical Officer · 33 transactions | — | 948.4K | 1.21M | 27.0K | 303.3K |
| Shalwitz RobertChief Medical Officer · 2 transactions | — | 727.1Kas of Mar 2014 | — | — | — |
| Ostrowski ErikSVP, CFO, CBO & Treasurer · 5 transactions | — | 672.6K | 748.9K | — | 76.3K |
| Dahan MichelSVP, Chief Operating Officer · 37 transactions | — | 672.1Kas of May 2024 | 861.8K | — | 244.5K |
| Hadas Nicole R.SVP, Chief Legal Officer · 44 transactions | — | 651.2Kas of May 2024 | 767.0K | 3.5K | 177.1K |
| Grund NicholasChief Commercial Officer · 6 transactions | — | 561.8K | 702.2K | — | 140.4K |
| Snow EllenSVP, CFO and Treasurer · 2 transactions | — | 519.3Kas of Jan 2024 | 519.3K | — | — |
| Spellman David ASVP, CFO and Treasurer · 12 transactions | — | 446.5Kas of May 2023 | 533.8K | — | 87.3K |
| Malabre Richard CSVP, Chief Accounting Officer · 9 transactions | — | 312.8K | 402.9K | — | 108.1K |
| Adams AdrianDirector · 9 transactions | — | 236.2K | 186.2K | 50.0K | — |
| Cotreau ViolettaSVP, Chief Accounting Officer · 5 transactions | — | 220.0Kas of May 2022 | 216.8K | — | 9.8K |
| Rogers Michael WDirector · 9 transactions | — | 197.4K | 197.4K | — | — |
| Smith CynthiaDirector · 10 transactions | — | 196.6K | 186.2K | 15.0K | 4.6K |
| Faulkingham DellSVP, CCO · 11 transactions | — | 174.8Kas of Mar 2022 | 201.2K | — | 27.3K |
| Rucci Carolyn M.SVP, Chief Legal Officer · 4 transactions | — | 171.8K | 190.0K | — | 69.8K |
| Wolf MylesDirector · 6 transactions | — | 169.1K | 158.8K | — | — |
| Frieson RonDirector · 6 transactions | — | 165.2K | 165.2K | — | — |
| Gilman Steven CDirector · 12 transactions | — | 152.8Kas of Jun 2025 | 160.7K | 5.8K | 13.7K |
| Zumwalt Leanne MDirector · 5 transactions | — | 145.1K | 145.1K | — | — |
| Amello JasonSVP, CFO & Treasurer · 10 transactions | — | 144.6Kas of Feb 2020 | 170.5K | 5.0K | 7.0K |
| Jain RitaSVP, Chief Medical Officer · 4 transactions | — | 96.3Kas of Apr 2019 | 109.4K | — | — |
| Tubridy Karen LSVP, Chief Development Officer · 7 transactions | — | 88.1Kas of Feb 2020 | 100.5K | — | 3.5K |
| Maroni BradleySVP and Chief Medical Officer · 2 transactions | — | 64.6Kas of Feb 2017 | 60.0K | — | — |
| Morrison Jodie PopeDirector · 2 transactions | — | 58.6Kas of Jun 2019 | 58.6K | — | — |
| Heffernan Michael ThomasDirector · 4 transactions | — | 48.6Kas of Jun 2021 | 48.6K | — | — |
| Enyedy Mark JDirector · 3 transactions | — | 31.1Kas of Jun 2020 | 31.1K | — | — |
| Gowen MaxineDirector · 4 transactions | — | 24.1Kas of Jun 2020 | 27.4K | 1.3K | 4.6K |
| Nash DuaneDirector · 19 transactions | — | 21.5Kas of Feb 2018 | 51.5K | — | 38.0K |
| Canute Scott ADirector · 1 transaction | — | 13.7Kas of Jun 2019 | 13.7K | — | — |
| Renaud Ronald C JRDirector · 1 transaction | — | 5.0Kas of Dec 2014 | — | 5.0K | — |
| Wyzga Michael SDirector · 1 transaction | — | 1.5Kas of Mar 2014 | — | 1.5K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -29.3K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.